Next Article in Journal
The Regulation of CIN-like TCP Transcription Factors
Next Article in Special Issue
Could Protons and Carbon Ions Be the Silver Bullets Against Pancreatic Cancer?
Previous Article in Journal
The Circulating Nucleic Acid Characteristics of Non-Metastatic Soft Tissue Sarcoma Patients
Previous Article in Special Issue
Drug Sequestration in Lysosomes as One of the Mechanisms of Chemoresistance of Cancer Cells and the Possibilities of Its Inhibition

Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma

Department of Oncology, University of Torino, 1026 Torino, Italy
Department of Computer Science, University of Torino, 10149 Torino, Italy
Department of Clinical and Biological Sciences, University of Torino, 10043 Orbassano, Italy
Laboratory of Experimental Oncology, Pharmacogenomics and Pharmacogenetics Research Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy
Candiolo Cancer Institute, FPO–IRCCS, 10060 Candiolo, Italy
Authors to whom correspondence should be addressed.
These authors equally contributed to this work.
Int. J. Mol. Sci. 2020, 21(12), 4500;
Received: 31 May 2020 / Revised: 19 June 2020 / Accepted: 21 June 2020 / Published: 24 June 2020
Doxorubicin (Dox) is one of the most important first-line drugs used in osteosarcoma therapy. Multiple and not fully clarified mechanisms, however, determine resistance to Dox. With the aim of identifying new markers associated with Dox-resistance, we found a global up-regulation of small nucleolar RNAs (snoRNAs) in human Dox-resistant osteosarcoma cells. We investigated if and how snoRNAs are linked to resistance. After RT-PCR validation of snoRNAs up-regulated in osteosarcoma cells with different degrees of resistance to Dox, we overexpressed them in Dox-sensitive cells. We then evaluated Dox cytotoxicity and changes in genes relevant for osteosarcoma pathogenesis by PCR arrays. SNORD3A, SNORA13 and SNORA28 reduced Dox-cytotoxicity when over-expressed in Dox-sensitive cells. In these cells, GADD45A and MYC were up-regulated, TOP2A was down-regulated. The same profile was detected in cells with acquired resistance to Dox. GADD45A/MYC-silencing and TOP2A-over-expression counteracted the resistance to Dox induced by snoRNAs. We reported for the first time that snoRNAs induce resistance to Dox in human osteosarcoma, by modulating the expression of genes involved in DNA damaging sensing, DNA repair, ribosome biogenesis, and proliferation. Targeting snoRNAs or down-stream genes may open new treatment perspectives in chemoresistant osteosarcomas. View Full-Text
Keywords: osteosarcoma; doxorubicin; chemoresistance; small nucleolar RNAs osteosarcoma; doxorubicin; chemoresistance; small nucleolar RNAs
Show Figures

Graphical abstract

MDPI and ACS Style

Godel, M.; Morena, D.; Ananthanarayanan, P.; Buondonno, I.; Ferrero, G.; Hattinger, C.M.; Di Nicolantonio, F.; Serra, M.; Taulli, R.; Cordero, F.; Riganti, C.; Kopecka, J. Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma. Int. J. Mol. Sci. 2020, 21, 4500.

AMA Style

Godel M, Morena D, Ananthanarayanan P, Buondonno I, Ferrero G, Hattinger CM, Di Nicolantonio F, Serra M, Taulli R, Cordero F, Riganti C, Kopecka J. Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma. International Journal of Molecular Sciences. 2020; 21(12):4500.

Chicago/Turabian Style

Godel, Martina, Deborah Morena, Preeta Ananthanarayanan, Ilaria Buondonno, Giulio Ferrero, Claudia M. Hattinger, Federica Di Nicolantonio, Massimo Serra, Riccardo Taulli, Francesca Cordero, Chiara Riganti, and Joanna Kopecka. 2020. "Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma" International Journal of Molecular Sciences 21, no. 12: 4500.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop